InvestorsHub Logo
Followers 16
Posts 303
Boards Moderated 0
Alias Born 04/29/2006

Re: None

Tuesday, 09/05/2017 4:38:11 PM

Tuesday, September 05, 2017 4:38:11 PM

Post# of 1394
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor
Clinical-Stage Asset in Validated Class of Drugs with Demonstrated Value

Potent Inhibitor of CDK9, 4/6 & 1, Potential to Overcome Resistance to BCL-2 Inhibitors

Opportunity in Combination with Venetoclax in CLL, Other Hematologic Indications


http://www.prnewswire.com/news-releases/mei-pharma-announces-exclusive-license-agreement-with-presage-biosciences-for-voruciclib-an-oral-selective-cdk-inhibitor-300514113.html


Shakedown

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MEIP News